Obracin (Tobramycin)

Obracin (tobramycin) is used to treat infections caused by Gram‑negative bacteria and specific respiratory conditions in cystic fibrosis.

• Severe Gram‑negative infections: Provides bactericidal activity to eradicate the pathogen.
• Cystic fibrosis pulmonary infections: Reduces bacterial load in the airways, improving lung function.
• Other serious infections caused by susceptible organisms: Achieves clinical cure when alternative agents are limited.

• Obracin (tobramycin) binds to the 30S subunit of bacterial ribosomes, causing misreading of messenger RNA and premature termination of protein synthesis. This disruption leads to rapid bactericidal activity against susceptible Gram‑negative organisms. The drug’s affinity for bacterial ribosomal sites exceeds that for eukaryotic cells, contributing to its selective toxicity.

Obracin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nephrotoxicity: reversible increase in serum creatinine or reduced urine output.
• Ototoxicity: transient tinnitus or hearing threshold shifts.
• Injection site reactions: pain, erythema, or swelling at the administration site.
• Neuromuscular blockade: muscle weakness, especially with high doses.

Serious or Rare Side Effects

• Acute renal failure: sudden loss of kidney function requiring dialysis.
• Permanent hearing loss: irreversible auditory damage after prolonged therapy.
• Severe allergic reactions (anaphylaxis): rash, bronchospasm, hypotension.
• Balance disorders: vertigo or loss of equilibrium.

When using Obracin, clinicians should observe several safety precautions to minimize risk.

• Renal function monitoring: assess serum creatinine and urine output before and during therapy.
• Auditory testing: perform baseline and periodic hearing assessments, especially in prolonged treatment.
• Concomitant nephrotoxic drugs: avoid or adjust dose when used with other renal‑toxic agents.
• Dosage adjustment in the elderly: reduce dose or extend interval based on renal clearance.
• Pregnancy and lactation: use only if clearly needed, as safety data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Obracin can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid)

• Loop diuretics: increase risk of nephrotoxicity.
• Other aminoglycosides: additive ototoxic and nephrotoxic effects.
• Neuromuscular blocking agents: potentiate muscle weakness and respiratory depression.

Moderate Interactions (Monitor Closely)

• Vancomycin: combined renal toxicity may require dose modification.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate kidney injury.
• Radiographic contrast media: heightened risk of acute kidney injury.